| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers I > Headlines for Idera Pharmaceuticals, Inc. > News item |
Idera expands portfolio of Toll-Like Receptors, presents data at AAI meeting
By Lisa Kerner
Erie, Pa., May 15 - Idera Pharmaceuticals said it has expanded its portfolio of drug candidates targeting Toll-like Receptors (TLRs) to include novel RNA compounds that activate immune responses through TLR7 and TLR8 and novel DNA compounds that act to inhibit activity of TLR9.
"Modulation of immune responses through TLRs is a powerful and broadly applicable therapeutic platform," chief executive officer and chief scientific officer Sudhir Agrawal said in a company news release.
"Our most advanced programs are with agents that activate immune responses through TLR9. We are evaluating these agents for potential applications in cancer, infectious disease and, through an alliance with Novartis, in asthma/allergy."
The company described its novel TLR research in three presentations at the Annual Meeting of the American Association of Immunologists in Boston.
Abstract number 853 ("RNAs containing novel structures and chemical modifications as potent agonists of Toll-like receptors 7 and 8") describes how drug candidates targeting TLR7 and TLR8 have potential application in numerous therapeutic areas including cancer, infectious disease, and in combinations with vaccines.
Idera's abstract number 1166 ("Synthetic antagonists of TLR9: In vitro and in vivo studies") demonstrates that novel synthetic compounds based on DNA structures inhibited immune responses through TLR9 in a dose-dependent fashion.
Results presented in Idera's abstract number 32 ("Application of synthetic agonists of TLR9 as adjuvants for several antigens, including influenza, H. pylori and Hepatitis B-virus antigens") show that TLR9 agonists may be useful agents in combinations with vaccines for infectious diseases and for cancer.
Idera, a Cambridge, Mass.-based biotechnology company, discovers, develops and commercializes targeted immune therapies based on modulation of Toll-like Receptors.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.